Recently, the 5th BioCentury China Healthcare Summit hosted by the Chinese elite organization in the global life sciences and medical health industry was held in Hong Kong. China Renaissance Group won the “Best Deal of the Year” award at The BayHelix Group's 2018 China Medical Award for its performance as Novocure's exclusive financial advisor in Novocure's (NASDAQ: NVCR) and Ding Ding Pharmaceutical (NASDAQ: ZLAB) transactions. ".

The BayHelix China Medical Award to recognize the achievements and contributions of individuals and companies in the pharmaceutical field in China. In its award speech to China Renaissance Group, The BayHelix Group wrote: “The cooperation between Novocure and Dingding Pharmaceuticals marks a 'creative strategic partnership'

China Renaissance Group is very optimistic about the field of medical and life sciences. In 2015, it established a medical and life science and technology team, focusing on mobile Internet medical and specialist hospitals, medical equipment, medical services, medicine and biotechnology, diagnosis and genetic testing. It is closely linked to the most cutting-edge direction in the field of medical and life sciences in China and around the world.

As of March 31, 2018, China Renaissance Group Medical and Life Science and Technology team has dozens of professionals, serving as a trading consultant for more than 50 medical private equity financing and mergers and acquisitions, and has established deep relationships with more than 200 medical-focused investors; Ten sub-sectors covering more than 300 companies.

.